期刊中文名:當代臨床(chuang)試驗通訊ISSN:2451-8654
該雜(za)志國(guo)際簡稱:Cont Clin Trial Comm,是由(you)出版(ban)商Elsevier出版(ban)的(de)(de)一(yi)本致(zhi)力于發布--研究新(xin)成(cheng)果(guo)的(de)(de)的(de)(de)專業(ye)學(xue)術(shu)期刊(kan)。主要發表刊(kan)登有創見(jian)的(de)(de)學(xue)術(shu)論文(wen)文(wen)章、行業(ye)最(zui)新(xin)科(ke)研成(cheng)果(guo),扼(e)要報道階段性(xing)研究成(cheng)果(guo)和重要研究工作的(de)(de)最(zui)新(xin)進展(zhan),選載(zai)對學(xue)科(ke)發展(zhan)起指導作用的(de)(de)綜述與專論,促(cu)進學(xue)術(shu)發展(zhan),為廣大(da)讀者服務。該刊(kan)是一(yi)本國(guo)際優秀雜(za)志,在國(guo)際上(shang)有很高的(de)(de)學(xue)術(shu)影響力。
《Contemporary Clinical Trials Communications》是一本(ben)以English為(wei)主的(de)(de)(de)開放獲取國際優秀期刊(kan)(kan)(kan),中文名稱當代臨(lin)床試驗通(tong)訊,本(ben)刊(kan)(kan)(kan)主要出(chu)版、報(bao)道領(ling)域(yu)(yu)的(de)(de)(de)研(yan)究動態以及在(zai)該(gai)領(ling)域(yu)(yu)取得(de)的(de)(de)(de)各方面的(de)(de)(de)經(jing)驗和科研(yan)成果,介紹該(gai)領(ling)域(yu)(yu)有關(guan)本(ben)專業的(de)(de)(de)最新(xin)進展(zhan),探討行業發展(zhan)的(de)(de)(de)思路和方法,以促進學術信(xin)息交流,提高行業發展(zhan)。該(gai)刊(kan)(kan)(kan)已被國際權威數(shu)據庫(ku)SCIE收錄,為(wei)該(gai)領(ling)域(yu)(yu)相關(guan)學科的(de)(de)(de)發展(zhan)起到了良好的(de)(de)(de)推動作用,也得(de)到了本(ben)專業人員的(de)(de)(de)廣泛認可。該(gai)刊(kan)(kan)(kan)最新(xin)影響因(yin)子為(wei)1.4,最新(xin)CiteScore 指數(shu)為(wei)2.7。
Contemporary Clinical Trials Communications is an international, peer-reviewed open access journal dedicated to the field of clinical trials. This journal aims to provide a high-quality communication platform for the design, implementation, analysis, and reporting of clinical trials, in order to promote the development of the fields of medicine and biological sciences. The main goal of the magazine is to publish original research, review articles, case reports, newsletters, conference reports, and other types of articles, covering various stages of clinical trials, including trial design, data collection, statistical analysis, result interpretation, and policy formulation. In addition, the magazine also focuses on ethical issues, patient safety, data management, and regulatory policies in clinical trials. Through high-quality research articles and providing a professional communication platform, this journal is committed to promoting the development of the fields of medicine and biological sciences, providing support for the design, implementation, analysis, and reporting of clinical trials.
按JIF指標學科分區 |
學科:MEDICINE, RESEARCH & EXPERIMENTAL
收錄子集:ESCI
分區:Q4
排名:144 / 189
百分位:
24.1% |
按JCI指標學(xue)科分區 |
學科:MEDICINE, RESEARCH & EXPERIMENTAL
收錄子集:ESCI
分區:Q4
排名:146 / 189
百分位:
23.02% |
JCR分區:JCR分(fen)(fen)區(qu)(qu)(qu)來自科睿唯安(an)公司,JCR是一(yi)個(ge)獨特的(de)多學科期刊(kan)評價工具,為唯一(yi)提供(gong)基于引文數(shu)據(ju)的(de)統計(ji)信息的(de)期刊(kan)評價資(zi)源。每(mei)年(nian)發布的(de)JCR分(fen)(fen)區(qu)(qu)(qu),設置(zhi)了254個(ge)具體學科。JCR分(fen)(fen)區(qu)(qu)(qu)根據(ju)每(mei)個(ge)學科分(fen)(fen)類按(an)照期刊(kan)當年(nian)的(de)影響因子高(gao)低將期刊(kan)平均(jun)分(fen)(fen)為4個(ge)區(qu)(qu)(qu),分(fen)(fen)別為Q1、Q2、Q3和Q4,各占25%。JCR分(fen)(fen)區(qu)(qu)(qu)中(zhong)期刊(kan)的(de)數(shu)量是均(jun)勻(yun)分(fen)(fen)為四個(ge)部分(fen)(fen)的(de)。
學科類別 | 分區 | 排名 | 百分位 |
大類:Medicine 小類:General Medicine | Q2 | 199 / 636 |
68% |
大類:Medicine 小類:Pharmacology | Q3 | 217 / 313 |
30% |
該雜(za)志(zhi)是(shi)一本(ben)國(guo)(guo)際優秀(xiu)雜(za)志(zhi),在(zai)國(guo)(guo)際上有較高的學(xue)術(shu)影響力,行業關(guan)注度很(hen)高,已被國(guo)(guo)際權威數(shu)據庫SCIE收錄,該雜(za)志(zhi)在(zai)綜合(he)專(zhuan)業領域專(zhuan)業度認可(ke)很(hen)高,對稿(gao)(gao)件內容(rong)的創新性和(he)學(xue)術(shu)性要求(qiu)很(hen)高,作為一本(ben)國(guo)(guo)際優秀(xiu)雜(za)志(zhi),一般投稿(gao)(gao)過(guo)審時(shi)間都(dou)較長,投稿(gao)(gao)過(guo)審時(shi)間平均 20 Weeks ,如(ru)果想(xiang)投稿(gao)(gao)該刊(kan)要做(zuo)好時(shi)間安排。版面(mian)費不祥。該雜(za)志(zhi)近兩(liang)年未被列入預警名單,建議(yi)您(nin)投稿(gao)(gao)。如(ru)您(nin)想(xiang)了解更多投稿(gao)(gao)政策及投稿(gao)(gao)方(fang)案,請咨(zi)詢(xun)客服(fu)。
若用戶(hu)需要(yao)出版服務,請聯系(xi)出版商。